We will review our assumptions when further details are released.
We maintain our valuation at SEK729m or SEK19.3/share and our forecasts are unchanged.
AlzeCure has reported positive Phase Ib data for its topical treatment for neuropathic pain, ACD440, slightly earlier than expected (mid-2021). These data show that the drug was well tolerated and demonstrated an efficacy signal of its analgesic potential. Preparations for Phase II development are underway. Regulatory filling for a new study, expected by end-2021, should provide a better sense of the forms of neuropathic pain AlzeCure will pursue.
LÄS MER